SAB Biotherapeutics, Inc. (SABS)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in SAB Biotherapeutics, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

SAB Biotherapeutics, Inc. (SABS) has returned 2.41% so far this year and 181.62% over the past 12 months.

Based on dividend-adjusted daily data since Feb 9, 2021, SABS's average daily return is -0.03%, while the average monthly return is -2.17%.

Historically, 37% of months were positive and 63% were negative. The best month was Apr 2023 with a return of +104.2%, while the worst month was Dec 2022 at -45.4%. The longest winning streak lasted 3 consecutive months, and the longest losing streak was 9 months.

On a daily basis, SABS closed higher 44% of trading days. The best single day was Apr 13, 2023 with a return of +99.7%, while the worst single day was Jan 28, 2025 at -52.5%.

SAB Biotherapeutics, Inc. has an annualized alpha of -14.05%, beta of 0.69, and R² of 0.01 versus S&P 500 Index. Calculated based on daily prices since February 10, 2021.

• This stock participated in 162.10% of S&P 500 Index downside but only -69.23% of its upside — more exposed to losses than it benefited from rallies.
• Beta of 0.69 may look defensive, but with R² of 0.01 this stock is largely uncorrelated with S&P 500 Index — low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
• R² of 0.01 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

SABS ranks 90 for risk / return — in the top 90% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.

The table below present risk-adjusted performance metrics for SAB Biotherapeutics, Inc. (SABS) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the SAB Biotherapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the SAB Biotherapeutics, Inc. was 99.01%, occurring on Apr 7, 2025. The portfolio has not yet recovered.

The current SAB Biotherapeutics, Inc. drawdown is 96.59%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of SAB Biotherapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how SAB Biotherapeutics, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.